You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美銀美林:升百濟神州(6160.HK)目標價至138.88港元 評級“買入”
格隆匯 11-18 15:34

美銀美林發表研究報告,指百濟神州(06160.HK)旗下淋巴癌新藥產品Brukinsa獲得美國藥監局(FDA)批准上市,預計未來兩週內可在美國開始銷售,考慮到Brukinsa在第III期試驗中,有較大機會治療效果好過同類產品,重申“買入”評級,目標價升至138.88港元

報告指,市場上同類產品Imbruvica及Calquence去年銷售額分別達30億美元及6,200萬美元,而Brukinsa的30天用量批發價為12,935美元,價格介於Imbruvica和Calquence之間。考慮到Brukinsa治療淋巴癌的效果會較Imbruvica好,未來美國銷售額增長可期。

該行並指出,百濟神州在美國銷售團隊有約100人,雖然規模將擴充至約150至200人,但美國團隊仍屬初成立,相信Brukinsa明年銷售額仍低於Calquence去年所錄約6,200萬美元銷售額。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account